Coombs (+); C3/C4 141/39. Pred 20, MMP 1000, HCQ. SLE4. 52/F. SLE. (No nephritis), Cr 0.48; arthritis, photosensitive ra
1
Table S1. Clinical and Laboratory Manifestations of SLE and Control Patients ID
Age/
Diagnosis
Clinical & Laboratory Findings
Medication (mg/d)
Gender SLE patients SLE1
27/M
SLE
Nephritis (IV)*, Cr 9.55; lymphopenia,
Pred 40, AZA 50, Aranesp
ANA, anti-DNA; Coombs (-)
(normal erythropoietin)
SLE2
50/M
SLE
Nephritis, anemia, ANA
Untreated
SLE3
54/F
SLE
Nephritis (V), Cr 0.77; seizures,
Pred 20, MMP 1000, HCQ
pancytopenia, ANA, antiDNA/Sm/RNP; Coombs (+); C3/C4 141/39 SLE4
52/F
SLE
(No nephritis), Cr 0.48; arthritis,
Pred 40, MMP 2000
photosensitive rash, leukopenia, serositis, ANA, anti-DNA/Sm/RNP; Coombs (+); C3/C4 82/14 SLE5
49/F
SLE
Nephritis (V), Cr 3.38; cerebritis,
Methylprednisolone pulse,
pancreatitis, pancytopenia, ANA, anti-
plasmapheresis, Pred 40
DNA; C3/C4 32/3 SLE6
32/F
SLE
Nephritis (IV), Cr 0.52, pancytopenia,
Pred 60, MMP 3000, HCQ
Coombs (+) AIHA, C3/C4 16/
